<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 44 out of 758 patients (5.8%) with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> presenting between 1971 and 1982, the central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) was involved </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with a diffuse histology had a 7.6% (34/449) incidence of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement compared to 3.9% (10/257) for patients with nodular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In 63% of patients there was evidence of progressive systemic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> at the time of diagnosis of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease and in 23% <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapse occurred in clinical remission </plain></SENT>
<SENT sid="3" pm="."><plain>Bone marrow was involved in 34% of patients at diagnosis and in 52% at some time prior to the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> complications </plain></SENT>
<SENT sid="4" pm="."><plain>Cerebrospinal fluid cytology was positive in 63% and an elevated protein level was found in 95% of patients </plain></SENT>
<SENT sid="5" pm="."><plain>The median length of survival of the 44 patients was only 3.2 months, but patients who responded to treatment of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> survived significantly longer than those who showed no response or progressed on therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Complete response to <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> treatment was achieved in five patients, of whom none relapsed in the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> and two are long-term disease-free survivors </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis appears justified for patients with lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt's tumour</z:e>, and diffuse undifferentiated <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, who are at high risk of developing <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> complications </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with diffuse histiocytic, and diffuse poorly differentiated lymphocytic, <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who have bone marrow involvement may also benefit from <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis </plain></SENT>
</text></document>